about
The role of drug transporters in the kidney: lessons from tenofovirAccelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies.Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancerRaltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovirOptimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling.Antimalarial 4(1H)-pyridones bind to the Qi site of cytochrome bc1Antimalarial pharmacology and therapeutics of atovaquoneRational Design, Synthesis, and Biological Evaluation of Heterocyclic Quinolones Targeting the Respiratory Chain of Mycobacterium tuberculosis.Antitubercular pharmacodynamics of phenothiazinesInteractions between tenofovir and nevirapine in CD4+ T cells and monocyte-derived macrophages restrict their intracellular accumulation.Rilpivirine inhibits drug transporters ABCB1, SLC22A1, and SLC22A2 in vitroEfavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation.Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies.Simulating Intestinal Transporter and Enzyme Activity in a Physiologically Based Pharmacokinetic Model for Tenofovir Disoproxil Fumarate.A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication.Predicting intestinal absorption of raltegravir using a population-based ADME simulation.Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter.Divalent metals and pH alter raltegravir disposition in vitro.Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism.Corrigendum: The role of drug transporters in the kidney: lessons from tenofovir.Development and validation of an LC-MS/MS assay for the quantification of efavirenz in different biological matrices.The biological challenges and pharmacological opportunities of orally administered nanomedicine delivery.Nanotechnologies in Pancreatic Cancer Therapy.The Application of Nanotechnology to Drug Delivery in MedicinePhysiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspectiveIntrapatient and Interpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting
P50
Q26866489-BF474941-670F-4941-8133-C5D0A54366E1Q28821119-3EF32AB1-A319-4951-9764-6F04B0E16F99Q33906118-F69A6B1B-BADA-4F25-B293-F6335145D6B6Q34529127-E0B0514B-491E-4FD5-B550-066C9816B2FBQ34571360-728F06F4-953B-44F7-A115-B36ED1D318C2Q35031417-91BCCD4D-D208-48D7-89CB-38DD6BC97E73Q35131253-E55107D8-AB6A-4017-963B-1D44C1ABA67FQ36311780-ED724E35-4884-4515-BF11-778EFE6409D7Q36675149-12CD1B54-00DD-48F2-8788-D23F448515EAQ37232200-501E795E-8392-4360-991E-40DF2A43A2AFQ37263486-0A8B3A52-1B9E-4296-9F9D-D831A154442DQ37538717-F0390472-822F-43F0-982F-BD363ABCA4BFQ38420688-7DE4A745-1C70-40BA-B563-B306D3990ACEQ38833637-527CF1D5-A447-48BE-9935-F512FAFFB555Q39273607-016FCB83-38CD-4BEC-A932-3ABE269A7E5FQ39273613-2E9152CF-237C-436D-A81A-E2C95F1629D6Q39489002-83C6D1D3-7807-4008-B6C6-82A534EE7FAFQ42189797-FF322FE6-2BDB-42EB-8052-BD396D703D58Q42760176-1639544D-561A-40FB-A2EE-BB82980100FDQ43138706-72997850-B756-42D9-BFA2-31CB2F1C4840Q47817799-D3B34C88-8901-4444-BDED-8C306D9C5255Q48093677-DE631B4A-41E4-4748-B542-44FDC9D36F28Q48293480-D9FD21CD-3F77-48CA-81C3-2B2533C412A2Q58073533-9D0F64B3-AE45-4EC8-A82B-83423E21A66EQ58073610-2AA51E4D-E580-439F-8820-93AF731FCCD9Q58073657-D33138DA-95C2-43C2-B7BE-88FB3CECF431
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Darren M Moss
@nl
Darren M Moss
@sl
Darren M. Moss
@en
Darren M. Moss
@es
type
label
Darren M Moss
@nl
Darren M Moss
@sl
Darren M. Moss
@en
Darren M. Moss
@es
prefLabel
Darren M Moss
@nl
Darren M Moss
@sl
Darren M. Moss
@en
Darren M. Moss
@es
P106
P1153
36667161800
P21
P31
P496
0000-0003-3981-6464